clinical trial · NCT06904248
Efficacy and Safety of Intravenous Meloxicam in Subjects With Moderate-to-severe Pain Following Abdominal Surgery
Yangtze River Pharmaceutical Group Co., Ltd.·phase3·completed·n = 224
Participants With Acute Moderate to Severe Pain Following Abdominal SurgeryMeloxicam InjectionSodium Chloride Injection
brief summary
This study aims to evaluate the analgesic efficacy and safety of meloxicam injection in subjects with moderate-to-severe pain following abdominal surgery. The primary efficacy endpoint is the summed pain intensity difference over 24 hours ( SPID24)
started
Jan 29, 2024
primary completion
Nov 20, 2024
completion
Feb 10, 2025
last updated
Apr 1, 2025
official title
Evaluation of the Efficacy and Safety of Meloxicam Injection for Postoperative Analgesia in Abdominal Surgery Patients: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 3 Clinical Trial
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol